Antagonistic selective binding agents of osteoprotegerin binding protein

Details for Australian Patent Application No. 2001238680 (hide)

Owner Amgen Inc.

Inventors Hitz, Anna; Deshpande, Rajendra V.; Boyle, William J; Sullivan, John Kevin

Agent Wrays

Pub. Number AU-B-2001238680

PCT Pub. Number WO01/62932

Priority 09791153 22.02.01 US; 09511139 23.02.00 US

Filing date 23 February 2001

Wipo publication date 3 September 2001

Acceptance publication date 22 February 2007

International Classifications

C12N 15/09 (2006.01) Mutation or genetic engineering - Recombinant DNA-technology

A61K 38/22 (2006.01) Medicinal preparations containing peptides - Hormones

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61K 45/00 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 3/14 (2006.01) Drugs for disorders of the metabolism

A61P 19/00 (2006.01) Drugs for skeletal disorders

A61P 19/02 (2006.01) Drugs for skeletal disorders

A61P 19/10 (2006.01) Drugs for skeletal disorders

A61P 29/00 (2006.01) Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

A61P 35/00 (2006.01) Antineoplastic agents

A61P 35/04 (2006.01) Antineoplastic agents

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

C07K 14/705 (2006.01) Peptides having more than 20 amino acids

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C12N 1/15 (2006.01) Micro-organisms, e.g. protozoa - modified by introduction of foreign genetic material

C12N 1/19 (2006.01) Micro-organisms, e.g. protozoa - modified by introduction of foreign genetic material

C12N 1/21 (2006.01) Micro-organisms, e.g. protozoa - modified by introduction of foreign genetic material

C12N 5/10 (2006.01) Undifferentiated human, animal or plant cells, e.g. cell lines - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

C12N 15/13 (2006.01) Mutation or genetic engineering - Immunoglobulins

C12P 21/08 (2006.01) Preparation of peptides or proteins - Monoclonal antibodies

Event Publications

22 February 2007 Application Accepted

  Published as AU-B-2001238680

21 June 2007 Standard Patent Sealed

23 December 2010 Extension of Term of Standard Patents

  Amgen Inc. The earliest first regulatory approval date provided by the patentee 07 Jun 2010 For the goods PROLIA denosumab

20 January 2011 Extension of Term of Standard Patents

  Amgen Inc. The earliest first regulatory approval date provided by the patentee 07 Jun 2010 For the goods PROLIA denosumab Address for service in Australia: Shelston IP 60 Margaret Street Sydney NSW 2000

16 June 2011 Extension granted

  Amgen Inc. The earliest first regulatory approval date provided by the patentee 07 Jun 2010 For the goods PROLIA denosumab Extension of Term of patent pursuant to Section 77 expires on 07 Jun 2025

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2001238682

2001238678